JPMorgan Chase and Co. lessened its holdings in QuidelOrtho Corporation (NASDAQ: QDEL) by 85.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 125,501 shares of the company's stock after selling 746,313 shares during the period. JPMorgan Chase
Quipt Home Medical (NASDAQ: QIPT - Get Free Report) and QuidelOrtho (NASDAQ: QDEL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Analyst Ratings This is a breakdown of
QuidelOrtho Corporation (NASDAQ: QDEL - Get Free Report) shares reached a new 52-week low during mid-day trading on Friday. The company traded as low as $14.75 and last traded at $15.0080, with a volume of 257918 shares. The stock had previously closed at $15.60. Analysts Set New Price Targets Several brokerages have commented on QDEL.
QuidelOrtho Corporation (NASDAQ: QDEL - Get Free Report) has been given an average rating of "Reduce" by the six ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating on the
SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions.
ArrowMark Colorado Holdings LLC lessened its position in QuidelOrtho Corporation (NASDAQ: QDEL) by 18.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 782,954 shares of the company's stock after selling 181,325 shares during the period. ArrowMark Colorado Holdings LLC owned about 1.15% of
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?
Rice Hall James purchased 574,877 shares of QuidelOrtho stock in the fourth quarter. The quarter-end position value grew by $16.2 million, reflecting both additional shares and price changes.
A board director at QuidelOrtho Corp. acquired 10,000 common shares on Feb. 13, 2026, at an average price of around $23.96 per share, totaling ~$240,000. All shares were acquired for direct ownership; indirect holdings via UGMA accounts and Birchview Fund, LLC, remain unchanged at 54,775 shares.
SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.
